Dr. Catherine Shu, MD
Claim this profileColumbia University
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
9 reported clinical trials
15 drugs studied
Area of expertise
1Lung Cancer
Stage IV
EGFR positive
Stage III
2Non-Small Cell Lung Cancer
Stage IV
EGFR positive
Stage III
Affiliated Hospitals
Clinical Trials Catherine Shu, MD is currently running
H002
for Non-Small Cell Lung Cancer
This is a phase I/IIa, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of H002 when given orally in patients with active EGFR mutation locally advanced or metastatic non-small cell lung cancer (NSCLC). The study will contain two parts: Part A is dose escalation phase (i.e., Phase I) and Part B is dose expansion phase (i.e., Phase IIa).
Recruiting1 award Phase 1 & 212 criteria
BCA101 + Pembrolizumab
for Cancer
This trial is testing BCA101, a new drug that targets specific cancer growth proteins, in patients with advanced cancers that haven't responded to other treatments. The drug works by blocking proteins that help the cancer grow and spread.
Recruiting1 award Phase 17 criteria
More about Catherine Shu, MD
Clinical Trial Related2 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Catherine Shu, MD has experience with
- Durvalumab
- Pembrolizumab
- Tremelimumab
- Osimertinib
- Ramucirumab
- Atezolizumab
Breakdown of trials Catherine Shu, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Catherine Shu, MD specialize in?
Catherine Shu, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are EGFR positive.
Is Catherine Shu, MD currently recruiting for clinical trials?
Yes, Catherine Shu, MD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Catherine Shu, MD has studied deeply?
Yes, Catherine Shu, MD has studied treatments such as Durvalumab, Pembrolizumab, Tremelimumab.
What is the best way to schedule an appointment with Catherine Shu, MD?
Apply for one of the trials that Catherine Shu, MD is conducting.
What is the office address of Catherine Shu, MD?
The office of Catherine Shu, MD is located at: Columbia University, New York, New York 10032 United States. This is the address for their practice at the Columbia University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.